Ethics in Psychedelic Therapy and Research
- Watch the fully captioned event recording.
- View the conversation on Twitter @PetrieFlom using #POPLAR.
Event Description
Psychedelic substances like psilocybin, MDMA, and ketamine are increasingly used in research and clinical medicine. By their very nature, they put patients in a vulnerable position. The altered state of consciousness produced by psychedelics can promote insight and healing. However, unscrupulous practitioners can also exploit patients when they are under the influence of these substances. Reports of abuse by licensed and underground psychedelic facilitators highlight these concerns.
On November 18th, ethicists, health care providers, and academic researchers gathered to discuss these risks and broader concerns regarding ethics in psychedelic therapy and research.
Panelists
- Introduction: Carmel Shachar, Executive Director, The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Oswald DeN. Cammann Fund at Harvard University.